St. Jude Fellowship Targets Pediatric Leukemia and Lymphoma Training at the Bedside and Bench
St. Jude Children’s Research Hospital is recruiting for a one-year Leukemia-Lymphoma Clinical MD Fellow in Memphis, placing advanced training in pediatric hematologic malignancies inside one of the most specialized centers in the field. The role is built for physicians who want deeper exposure to the diagnosis, evaluation, and management of leukemia, lymphoma, and other hematologic cancers in infants, children, adolescents, and young adults.
This is not a narrow observership. The fellowship is framed as hands-on clinical development in a division that treats complex blood cancers across childhood and young adulthood, where treatment decisions often depend on subtle differences in biology, risk, and recurrence patterns. In that setting, trainees learn more than protocols. They learn how to read disease behavior in real time.
Clinical Training Built Around Pediatric Hematologic Malignancy Care
The program is structured to strengthen clinical expertise in the diagnosis, evaluation, and management of hematologic malignancies across a broad pediatric and young-adult age range. Fellows are expected to work with leaders in the field while refining multidisciplinary care for children with diverse blood cancers.
That multidisciplinary emphasis matters in pediatric oncology because these diseases rarely sit within one specialty lane. Leukemia and lymphoma care frequently requires coordination across hematopathology, imaging, transfusion support, infection management, supportive care, and long-term follow-up. A fellow in this environment is trained to recognize how each component affects treatment delivery, toxicity, and relapse surveillance.
The fellowship also explicitly connects clinical work to the biology of disease. Trainees are expected to apply knowledge from basic laboratory and clinical research to improve understanding of pathogenesis, treatment response, and recurrence in pediatric hematologic malignancies. In practical terms, that means the program links bedside decisions with the molecular and cellular mechanisms that drive cancer persistence or return.
Recurrence is the critical fault line in blood cancer care. Pediatric leukemia and lymphoma may respond well initially, but resistant clones, sanctuary sites, and biologic heterogeneity can shift the course rapidly. A training model that pairs direct patient care with disease mechanism review gives fellows a clearer view of why one child responds while another relapses despite similar frontline therapy.
Fellowship Structure Reflects a High-Intensity Academic Setting
The one-year program includes participation in case conferences, lectures, and disease-oriented team meetings. Those settings are central in a hospital like St. Jude, where rare presentations, treatment complications, and evolving evidence often meet in the same room. They also teach clinical judgment in a way that chart review alone cannot.
Applicants are expected to be American Board of Pediatrics eligible or certified in pediatric hematology/oncology, or to have equivalent training as judged by the program directors. That threshold signals that the fellowship is designed for physicians already grounded in pediatric specialty care who want more concentrated exposure to malignant hematology.
A short training window makes precision essential. Fellows entering a one-year program need broad disease familiarity, but they also need the discipline to absorb institutional workflows, interpret complex laboratory and pathology data, and participate in multidisciplinary decision-making without losing sight of the child in front of them. This kind of fellowship typically favors physicians who can move comfortably between consultative reasoning and longitudinal care.
St. Jude’s Patient Population Shapes the Training Experience
St. Jude describes itself as one of the world’s premier centers for pediatric catastrophic illness, with a primary emphasis on childhood cancer, sickle cell disease, other hematologic conditions, infectious diseases, and pediatric neurologic disease. The hospital also serves an international patient population, which broadens exposure to different backgrounds, care needs, and family structures.
For a fellow, that diversity is not incidental. Pediatric hematologic malignancy care often depends on communication across cultures, languages, and health-system expectations, especially when families travel long distances for treatment. Working in that environment can sharpen a clinician’s ability to explain risk, anticipate barriers, and support families through prolonged therapy.
St. Jude is also described as the first and only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. In a fellowship centered on blood cancers, that institutional identity carries direct clinical relevance: pediatric oncology is not a side service here, but the core mission.
Support Package and Application Requirements Signal a Research-Clinical Hybrid Role
The fellowship includes a professional development allowance, research allowance, a personal computer for fellowship use, tuition assistance, dependent care assistance, moving allowance, employer-contributed retirement savings, and medical, dental, and vision insurance with cost sharing. Disability coverage, long-term disability, a group life insurance benefit, flexible health and dependent care savings accounts, and access to an onsite health and fitness facility are also included.
Those benefits suggest an employer trying to support both clinical immersion and academic productivity. Research time and professional development funding are especially relevant in pediatric hematology/oncology, where fellowship often doubles as a launch point for future investigator-educators or subspecialists with a strong scholarly agenda.
Applicants are asked to provide a personal statement, curriculum vitae, three original letters of recommendation submitted directly by referees, USMLE transcript, medical school transcripts, and ECFMG certification if applicable. The application window is open, and interviews are described as flexible, though the typical season occurs in the fall for a July 1 start.
Memphis is presented as an affordable location with cultural and recreational amenities, a practical detail for physicians relocating for training. In fellowship decisions, geography is rarely secondary. Housing costs, family support, and access to daily life outside the hospital can influence whether a high-intensity training year is sustainable.
What This Fellowship Means for Pediatric Hematology-Oncology Training
Programs like this matter because pediatric leukemia and lymphoma care depends on physicians who can integrate pathology, biology, supportive care, and longitudinal follow-up without fragmentation. The field moves quickly, but the child’s course rarely does. Treatment intensity, complications, and relapse risk can evolve over months, not days, and training has to match that complexity.
A fellowship embedded in a major pediatric cancer center offers exposure to that reality in concentrated form. It prepares physicians not only to manage hematologic malignancies, but to understand how institutional expertise, research integration, and multidisciplinary practice shape outcomes for children and young adults facing some of the most serious cancers in medicine.